Major Depressive Disorder
Wiki Number: PW115
Diagnosis: Major Depressive Disorder
World Patients: 163 Mil; 2% of world population
Sex Ratio: M;W2
Age Onset: 20s-30s; The average duration is 23 weeks, with three more during lifetime. ½ of patients will not have another episode.
Brain Area: 102 variations in the genome linked to depression; There is an extensive description of possible brain affects on depression.
Symptoms: Has at least two weeks of depressive mood; inability to enjoy pleasure; rumination; reduced sex drive, insomnia and hypersomnia
Progression: weight and appetite may be low; fatigue, social withdrawal, suicidal thoughts; delusions or sometimes hallucinations
Causes: 40%-hereditary; response to stressors, childhood abuse. The article claims general physicians miss 2/3 of depression diagnoses.
Medications: Antidepressants-for the deeply depressed; electroconvulsive therapy
Therapies: Counseling; transcranial magnetic stimulation, light therapy, exercise, light therapy,
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Crisis Psychotherapy Treatment of a Cancer Survivor With Suicidal Ideation During the COVID-19 Pandemicby Irina Mindlis on October 26, 2021
- Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signatureby Christopher R Brydges on October 26, 2021
It is unknown whether indoles, metabolites of tryptophan that are derived entirely from bacterial metabolism in the gut, are associated with symptoms of depression and anxiety. Serum samples (baseline, 12 weeks) were drawn from participants (n = 196) randomized to treatment with cognitive behavioral therapy (CBT), escitalopram, or duloxetine for major depressive disorder. Baseline indoxyl sulfate abundance was positively correlated with severity of psychic anxiety and total anxiety and with...
- Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical studyby Nagahide Takahashi on October 26, 2021
CONCLUSIONS: Efficacy of esketamine plus oral AD in Japanese TRD patients was not established; further investigation is warranted. All esketamine doses were safe and tolerated.
- Using self-report RDoC measures to identify transdiagnostic translational targets for perinatal affective disordersby Elizabeth S Wenzel on October 26, 2021
Perinatal depression affects 6.5-12.9% of women, with high rates in women of color and comorbid perinatal anxiety in up to 50% of cases. The Research Domain Criteria (RDoC) provides a translational framework for identifying transdiagnostic psychiatric symptoms, but its application in perinatal affective disorders (PNAD) is yet limited. Here, we identified RDoC-based transdiagnostic features of PNAD in 140 primarily low-income Black and Hispanic women at 272 total longitudinal visits across the...